Alio Jorge L, Rodriguez Alejandra E, Abdelghany Ahmed A, Oliveira Renan F
Division of Ophthalmology, School of Medicine, Universidad Miguel Hernández, Alicante, Spain.
Refractive Surgery Department, VISSUM, Alicante, Spain.
J Ophthalmol. 2017;2017:2457620. doi: 10.1155/2017/2457620. Epub 2017 Dec 12.
To evaluate the efficacy of autologous platelet-rich plasma (E-PRP) eye drops for the treatment of chronic ocular surface syndrome (OSS) following laser in situ keratomileusis (LASIK).
This prospective interventional consecutive clinical study include 156 eyes of 80 patients affected by post-LASIK chronic OSS who were treated with autologous E-PRP 6 times a day as monotherapy for 6 weeks.
Dry eye symptoms improved in 85% of the cases. A decrease in at least one quadrant to total disappearance on CFS was observed in 89.6% of the patients who had positive CFS before treatment. Three eyes presented severe punctate keratitis (1.9%) at baseline, all of which healed completely. Conjunctival hyperemia improved in 93.3% of the patients with previous signs of ocular surface inflammation. There was a significant improvement in logMAR CDVA from 0.14 ± 0.19 to 0.06 ± 0.12 ( = 0.000), and 74 (71.4%) eyes improved at least 1 line in CDVA.
Monotherapy with autologous E-PRP is a well-tolerated, safe, and effective treatment for the management of post-LASIK ocular surface syndrome.
Monotherapy with autologous platelet-rich plasma eye drops has been shown to be an adequate option for the treatment of post-LASIK chronic ocular surface syndrome. This trial is registered with NCT03322917.
评估自体富血小板血浆（E-PRP）滴眼液治疗准分子原位角膜磨镶术（LASIK）后慢性眼表综合征（OSS）的疗效。
这项前瞻性干预连续性临床研究纳入了80例受LASIK术后慢性OSS影响的患者的156只眼，将自体E-PRP作为单一疗法，每天滴眼6次，持续6周。
85%的病例干眼症状得到改善。治疗前角膜荧光素染色（CFS）阳性的患者中，89.6%的患者至少一个象限的染色减少至完全消失。3只眼在基线时出现严重点状角膜炎（1.9%），所有这些眼均完全愈合。93.3%有眼表炎症迹象的患者结膜充血得到改善。LogMAR矫正视力（CDVA）从0.14±0.19显著改善至0.06±0.12（P = 0.000），74只眼（71.4%）的CDVA至少提高了1行。
自体E-PRP单一疗法是治疗LASIK术后眼表综合征耐受性良好、安全有效的方法。
自体富血小板血浆滴眼液单一疗法已被证明是治疗LASIK术后慢性眼表综合征的一种合适选择。本试验已在ClinicalTrials.gov注册，注册号为NCT03322917。
